Quintrio
Home

PHARMACEUTICAL PREPARATIONS

United Therapeutics Corp

UTHR

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Last trade $579.52
Day change -$8.365 (-1.42%)
Day range $575.99 – $590.35
Volume 154,895
Market cap $25.04B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$25.04B
Price / earnings
20.34×
Price / book
3.99×
Price / sales
7.85×
EV / sales
7.48×
EV / EBITDA
16.83×

Profitability

Earnings per share
$28.90
Return on assets
17.5%
Return on equity
19.61%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.61×
Quick ratio
4.29×
Cash ratio
1.9×

Cash flow

Price / cash flow
17.51×
Price / free cash flow
28.87×
Free cash flow
$867.2M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for UTHR, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$832.5M$783.3M$781.5M$790.2M$799.5M$798.6M$794.4M$735.9M
Cost of revenue$99.1M$99.5M$133.4M$103.4M$100.9M$87.6M$92.5M$75.9M
Gross profit$733.4M$683.8M$648.1M$686.8M$698.6M$711M$701.9M$660M
Selling, general and administrative$146.4M$206.7M$184.1M$190.6M$182.6M$212.5M$170.1M$168.5M
Research and development$279.2M$146.3M$138.2M$139.5M$127.5M$134M$149M$133.8M
Total operating expenses$425.6M$353M$322.3M$330.1M$310.1M$346.5M$319.1M$302.3M
Operating income$307.8M$330.8M$325.8M$356.7M$388.5M$364.5M$382.8M$357.7M
Interest expense-$2.9M-$2.9M-$3M-$3.1M-$3M-$7.3M-$6.1M-$7.9M
Income before taxes$372.8M$372.7M$318.3M$444M$438M$408.4M$423.5M$396.5M
Income taxes$114.2M$39.7M$43.4M$79.7M$99.3M$98.9M$101.3M$95.2M
Net income$258.6M$333M$274.9M$364.3M$338.7M$309.5M$322.2M$301.3M
Net income attributable to common shareholders$258.6M$333M$274.9M$364.3M$338.7M$309.5M$322.2M$301.3M
EBITDA$334.2M$355M$348.4M$379.5M$410.4M$385.6M$402.6M$377.4M
Basic earnings per share$6.06$7.82$6.32$8.39$7.73$6.86$7.18$6.73
Diluted earnings per share$5.71$7.27$5.82$7.69$7.16$6.41$6.63$6.23

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

SGIOY or UTHR: Which Is the Better Value Stock Right Now?

In a comparison of two medical-drugs sector stocks, Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) emerges as the better value opportunity for investors compared to United Therapeutics (UTHR). SGIOY holds a Zacks Rank #2 (Buy) with stronger estimate revisions and more attractive valuation metrics, including a lower forward P/E ratio of 11.89 versus UTHR's 23.57, and a superior Value grade of B compared to UTHR's C grade.

GlobeNewswire Inc.

Robinson Helicopter Company Exhibits Broadened Portfolio of Manned and Unmanned Helicopters at European Rotors in Lyon December 1-3, 2026 – Stand #165

Robinson Helicopter Company will showcase its expanded portfolio of manned and unmanned helicopters at European Rotors 2026 in Lyon, France (December 1-3). The exhibition will feature the European debut of the R44 Raven II Utility, R22, and R66 helicopters, along with unmanned systems (HELIUS, SPIRIT, SPARTAN). Robinson will also host a panel discussion on single-engine helicopter safety and operations in European airspace, featuring executives from Robinson, Safran Helicopter Engines, and aviation experts.

Zacks Investment Research

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported strong Q3 2026 results with earnings of 80 cents per share and revenues of $225.3 million, driven by Yutrepia sales of $222.7 million. However, a $389.7 million litigation settlement with United Therapeutics restricts Yutrepia's promotion to pulmonary arterial hypertension only, eliminating PH-ILD commercialization. The company maintains confidence in PAH growth and has sufficient cash reserves to support settlement payments and pipeline expansion.

Zacks Investment Research

LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook

Liquidia Corporation (LQDA) reported Q3 2026 revenues of $225.3M, surging 314.6% year-over-year, with YUTREPIA sales reaching $222.7M, up 31% sequentially. The company achieved record October patient shipments and expanded its prescriber base to 1,300 despite temporary referral disruptions following a settlement with United Therapeutics. Management maintained a 94% gross margin and plans to provide 2027 revenue guidance in January.

Zacks Investment Research

United Therapeutics (UTHR) Q3 Earnings Miss Estimates

United Therapeutics reported Q3 2026 earnings of $5.71 per share, missing the consensus estimate of $5.85, representing a -2.39% surprise. However, the company exceeded revenue expectations with $832.5 million versus the estimate of $783.3 million. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical - Drugs industry ranks in the top 41% of Zacks industries.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 23, 20092-for-1forward split